Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

der(11)t(1;11)(q11-23;q14-25)

Written2015-12Adriana Zamecnikova, Soad Al Bahar
Kuwait Cancer Control Center, Department of Hematology annaadria@yahoo.com

Keywords chromosome 1; chromosome 11; hematologic malignancies; multiple myeloma; myelodysplastic syndrome; biphenotypic acute leukaemia; acute myeloid leukemia; acute lymphoblastic leukaemia.

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9811/3 B lymphoblastic leukaemia/lymphoma, NOS
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
ICD-Morpho 9975/3 Chronic myelogenous leukaemia, BCR-ABL1 positive; Myeloproliferative neoplasm, unclassifiable; Myelodysplastic/myeloproliferative neoplasm, unclassifiable
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
Atlas_Id 1651
Note The reciprocal t(1;11)(q21;q23) translocation fuses the KMT2A (MLL) gene to MLLT11 (AF1q) on chromosomal band 1q21

Clinics and Pathology

Disease De novo or secondary acute myeloid leukemia (AML) and acute lymphoblastic leukaemia (ALL), biphenotypic acute leukaemia (BAL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphoid malignancies.
Phenotype / cell stem origin 13 patients were diagnosed with myeloid malignacies: AML 6 cases (Najfeld et al., 1978; Archimbaud et al., 1998; Harrison et al., 1998; Stark et al., 2004), MDS 5 cases (González et al., 1992; von Bergh et al., 2000; Lange et al 2010; Dambruoso et al., 2012; Harrison et al., 1998), polycythemia vera 1 patient (Douet- Guilbert et al., 2008) and chronic myelomonocytic leukemia 1 case (Muroi et al., 1996). Among them, 4 cases were identified as secondary diseases (Muroi et al., 1996; Archimbaud et al., 1998; Harrison et al., 1998). There were 6 patients with ALL (Kaneko et al., 1982; Mamaeva et al., 1983; Lorenzana et al., 1991; Harrison et al., 1998; Betts et al., 2001; Wan et al., 2004), one of them was a secondary leukaemia (Harrison et al., 1998) and there were 3 biphenotypic leukaemias (Hayhashi et al., 1990; Forrest et al., 1998; Jarvis et al., 1999). Chronic lymphocytic leukemia was diagnosed in 2 patients (Qian et al., 1999; Travella et al., 2013), one of them transformed to Non hodgkin's lymphoma (Qian et al., 1999). 5 additional cases were diagnosed with lymphoma (Tien et al., 1997; Jerkeman et al., 1999; Le Baccon et al., 2001; Dave et al., 2002; Narayan et al., 2013). The remaining patients were (1 case each) multiple myeloma (Lim et al., 2013), plasma cell leukemia (Avet-Loiseau et al., 2001), T-prolymphocytic leukemia (Yamaguchi et al., 2003) and aggressive natural killer-cell leukemia (Ryder et al., 2007).
Table 1. Reported patients with der(11)(q11-q23;q14-25) in hematologic malignancies

 

Sex/ Age

Disease

Karyotype

 

Myeloid malignancies

1

M/38

Preleukemia AML

46,XY,der(11)t(1;11)(q11-12;q25)50,XX,+6,+8,+9,der(11),+18,+del(19)(p?),+20,+mar

2

M

RARS

46,XY,der(11)t(1;11)(q12;q23)

3

M/19

s-CMMoL

46,XY,der(11)t(1;11)(q21;q14)

4

M

s-AML

75,XXYY,-2,-3,+4,-10,der(11)t(1;11)(q21;q23)x2,-12,-14,-14,-15,-15,-16,-17,i(17)(q10),+18, del(20)(q11)x2,10-25dmin

5

M/18

s-MDS

47,XY,der(11)t(1;11)(q21;q23),+mar/48,idem,+mar

6

F/48

s-AML

44,XX,-3,-5,-7,del(9)(p13),der(11)t(1;11)(q21;q23),-18,+2mar

7

M/62

AML

75,XXYY,,3n.,+1,+4,+4,+5,+6,+7,+8,+9,der(11)t(1;11)(q21;q23)x2,+13,-14,-5,i(17)(q10), +18,+18,+19,+20,del(20)(q12)x2,dmin

8

M/22

AML- M5b

46,XX,der(11)t(1;11)(q31;q23)

9

M/31

MDS

s 46,XY,der(11)t(1;11)(q21;q23)/46,idem,add(6)(p21)

10

F

AML

47,XX,+8,del(9)(q12q22),der(10)t(10;11)(p13;q23)/47,idem,der(11)t(1;11)(q23;q23)/ 46,XX,der(7)t(3;7)(?;p22),t(9;10)(p22;p1? 5),der(11)t(10;11),-13,+22

11

M/60

PV

s 46,XY,der(11)t(1;11)(q12;q14)/46,XY,del(20)(q12)

12

M/65

RAEBI

47,XY,+8,der(11)t(1;11)(q21;q14-21)

13

F/65

RAEBI

46,X,add(4)(q23),del(20)(q12),+mar/46,idem,der(11)t(1;11)(q11;q25)

 

Acute lymphocytic leukemia

14

M/4

ALL

46,XY,der(11)t(1;11)(q21;q14)

15

F/62

ALL

46,XX,der(11)t(1;11)(q21;q23)

16

M

BP-ALL

51,XY,+6,+der(11)t(1;11)(q21;q23),+19, +21,+22

17

F/8

ALL

46,XX,add(4)(q35),t(9;11)(p22;q23),der(11)t(1;11)(q21;q14)

18

M/21

BP-ALL

46,XY,der(11)t(1;11)(q21;q23) BMT A 84

19

F/36

s- B-ALL

46,XX,der(11)t(1;11)(q21;q23),t(12;17)(p13;q21)

20

M/16

BP-ALL

46,XY,der(6)t(1;6)(q23;p21)/46,XY,der(11)t(1;11)(q23;q21)

21

M

ALL

63,XXY,-1,-2,-3,-7,-9,+10,der(11)t(1;11)(q12;q22),-13,-15,+18,-19,-20,+21/61-66,idem,+2

22

M/50

B-ALL

45,XY,der(9)t(9;22)(q34;q11),-10,der(11)t(1;11)(q12;q25),+14,der(14;22) t(14;20)(p13;p13) t(9;22),der(15)t(1;15)(q12;p13),der(19)t(1;19)(q12;p13), der(20)t(1;20)(q12;p13),-21

 

Other hematological neoplasms

23

M/70

PCL

45,XY,der(5;20)(p10;p10),der(11)t(1;11)(q12;q23),t(11;14)(q13;q32),-13,der(20)t(5;20) (q10;p10)dup(5)

24

M/60

T-PLL

42,XY,add(1)(q21),add(7)(q22),i(8)(q10),-9,der(11)t(1;11)(q21;q23),del(12) (p12),-13,-14, -15,add(17)(p13),add(18)(q23),-22,+mar/42,idem,+8,+15, add(21)(p11)/47,XY,+21

25

M/36

ANKL

48,XY,+3,der(11)t(1;11)(q21;q25),add(22)(q13),+mar/50,idem,+13,+20

26

F

MM

55-57,XX,+X,-X,der(X;14)(q10;q10),der(1)del(1)(q21q32)inv(1)(q13q32),+3,+5,+6,+7,-8, +9,+11,der(11)t(1;11)(q12;q25),+add(12)(p11),+13,+15,+18, +18,+19, +19,+21,+22,+1-2mar

27

M/40

CLL

46,XY,del(6)(q13q21),del(7)(q22q34),-8,add(9)(q34),del(9)(q22),der(11)t(1;11)(q21;q23),-17,+r,dmin

 

Lymphomas

28

F/37

ENK/T-cell

47,X,-X,der(1)t(1;14)(p22;q11),-2,i(6)(p10),del(7)(q31q36),add(8)(p23), der(11)t(1;11) (q11;q25),-18,+20,+21,-22,+3mar/49,idem,+i(6)(p10),+del(7)(q31q36) LN

29

F/78

DLBCL

43,XX,-1,?dup(3)(q21q27),der(11)t(1;11)(q23;q13),der(14)t(11;14)(q13;q32),-21 LN

30

F

CLL- NHL

47,XX,+12,t(14;19)(q32;q13)47,XX,der(11)t(1;11)(q12;q25),+12,t(12;22),t(14;19)/47,idem,add(10)(q24)LN

31

M/84

FL

48,XY,+X,der(11)t(1;11)(q12;q24),t(14;18)(q32;q21),+der(18)t(14;18)LN

32

F

DLBCL

50,XX,+X,der(2)t(2;15)(p13;q13),der(11)t(1;11)(q21;q25),+12,+del(13)(q14),der(14)t(14;15)(q32;q22),der(15)t(2;15)(p23;q13),der(16)t(7;16)(q22;q22), der(22)t(2;22)(q33;p11) LN

33

M/70

DLBCL

47,XY,del(3)(q22q25),t(4;9)(q21;q34),del(6)(q16q23),del(9)(q34),der(11)t(1;11)(q21;q13), del(12)(q22q23),+18,add(19)(q13)/46,XY,del(20)(q12)


Abbreviations: M, Male; F, Female; AML, Acute myeloid leukemia; RARS, Refractory anemia with ringed sideroblasts; CMMoL, Chronic myelomonocytic leukemia; s-, secondary; MDS, myelodysplastic syndrome; PV, polycythemia vera; RAEBI, Refractory anemia with excess blasts-1; ALL, acute lymphoblastic leukemia; BP, Bilineage or biphenotypic leukemia; CLL, Chronic lymphocytic leukemia; PCL, Plasma cell leukemia; T-PLL, T-prolymphocytic leukemia; ANKL, Aggressive natural killer-cell leukemia; MM, Multiple myeloma; ENK/T, Extranodal NK/T-cell, NHL, Non-Hodgkin's lymphoma; DLBCL, Diffuse large B-cell lymphoma; FL, Follicular lymphoma; LN, lymph node.
1. Najfeld et al., 1978; 2. Gonz ález et al., 1992., 3. Muroi et al., 1996; 4. Archimbaud et al., 1998; 5-8,19. Harrison et al., 1998; 9. von Bergh et al., 2000; 10. Stark et al., 2004; 11. Douet- Guilbert et al., 2008; 12. Lange et al 2010; 13. Dambruoso et al., 2012; 14. Kaneko et al., 1982; 15. Mamaeva et al., 1983; 16. Hayhashi et al., 1990; 17. Lorenzana et al., 1991; 18. Forrest et al., 1998; 19. Harrison et al., 1998; 20. Jarvis et al., 1999; 21. Betts et al., 2001; 22. Wan et al., 2004; 23. Avet-Loiseau et al., 2001; 24. Yamaguchi et al., 2003; 25. Ryder et al., 2007; 26. Lim et al., 2013; 27. Travella et al., 2013; 28. Tien et al., 1997; 29. Jerkeman et al., 1999; 30. Qian et al., 1999; 31. Le Baccon et al., 2001; 32. Dave et al., 2002; 33. Narayan et al., 2013.
Epidemiology here was 22 male and 11 female patients (sex ratio 2:1). The most notable prevalence of male patients was in myeloid cases (10 males/3 females), while there were 6 male patients and 3 females with ALL. Most of the cases were adults with a median age of 44 years (range 8-84 years) for all patients. The median age in myeloid cases was 42.8 years (range 18 to 65 years) and 51.5 years in other neoplasms (range 36 to 70 years). The lowest median age was in ALL/biphenotypic leukemia patients (28.1 years, range 4 to 62 years) and the highest in lymphoma patients (67.2 years, range 37 to 84 years).
Prognosis Heterogeneous group of diseases; prognosis may depend on chronic versus advanced disease. One patient with BP-ALL was alive 84 months after bone marrow transplant (BMT) (Forrest et al., 1998), however 3 additional ALL patients (Mamaeva et al., 1983; Martineu et al., 1996; Harrison et al., 1998) as well the 3 myeloid cases have relapsed and died of the disease with extremely short survival, including the sMDS case with BMT who died after transformation to AML (Harrison et al., 1998). Therefore, the prognosis is likely unfavorable in acute leukemia patients and in patients with complex karyotypes.

Cytogenetics

Cytogenetics Morphological Unbalanced rearrangement, presents as 2 normal chromosomes 1, one normal chromosome 11 and a der(11)t(1;11) chromosome. Most patients presented with 1q21 (17 patients) and 11q23 breakpoints (15 patients), while the der(11)t(1;11)(q21;q23) was the most frequent rearrangement (11 out of 33 patients).
Additional anomalies Seven reported cases showed this translocation either as the sole abnormality (Najfeld et al., 1978; Kaneko et al., 1982; Mamaeva et al., 1983; González et al., 1992., Muroi et al., 1996; Forrest et al., 1998; Harrison et al., 1998; von Bergh et al., 2000) or as part of a simple karyotype in three cases (Harrison et al., 1998; von Berg et al., 2000; Lange et al 2010). In 2 patients, it was found in a sideline clone (Jarvis et al., 1999; Douet- Guilbert et al., 2008). SIn myeloid malignancies, a trisomy 8 was found in 4 cases (Najfeld et al., 1978; Harrison et al., 1998; Stark et al., 2004; Lange et al 2010), del(20q) in 4 patients (Archimbaud et al., 1998; Harrison et al., 1998; Douet- Guilbert et al., 2008; Dambruoso et al., 2012) and i(17)(q10) in 2 patients, both with near-triploid karyotypes (Archimbaud et al., 1998; Harrison et al., 1998). The t(9;22)(q34;q11) was found as an accompanying anomaly in one ALL case. A complex karyotype was present in all lymphoma patients, while the 14q32 rearrangement was found as an accompanying anomaly in 4 out of 6 lymphoma patients (Jerkmen et al., 1999; Qian et al., 1999; Le Baccon et al., 2001; Narayan et al., 2013).
Variants To include: Addition patients with alternative 1q and 11q breakpoints are included in Table 2

 

Sex/ Age

Disease

Karyotype

 

Myeloid malignancies

1

M/38

Preleukemia AML

46,XY,der(11)t(1;11)(q11-12;q25), 50,XX,+6,+8,+9,der(11),+18,+del(19)(p?),+20,+mar

2

M

RARS

46,XY,der(11)t(1;11)(q12;q23)

3

M/19

s-CMMoL

46,XY,der(11)t(1;11)(q21;q14)

4

M

s-AML

75,XXYY,-2,-3,+4,-10,der(11)t(1;11)(q21;q23)x2,-12,-14,-14,-15,-15,-16,-17,i(17)(q10),+18, del(20)(q11)x2,10-25dmin

5

M/18

s-MDS

47,XY,der(11)t(1;11)(q21;q23),+mar/48,idem,+mar

6

F/48

s-AML

44,XX,-3,-5,-7,del(9)(p13),der(11)t(1;11)(q21;q23),-18,+2mar

7

M/62

AML

75,XXYY,,3n.,+1,+4,+4,+5,+6,+7,+8,+9,der(11)t(1;11)(q21;q23)x2,+13,-14,-5,i(17)(q10),+18,+18,+19,+20,del(20)(q12)x2,dmin

8

M/22

AML- M5b

46,XX,der(11)t(1;11)(q31;q23)

9

M/31

MDS

s 46,XY,der(11)t(1;11)(q21;q23)/46,idem,add(6)(p21)

10

F

AML

47,XX,+8,del(9)(q12q22),der(10)t(10;11)(p13;q23)/47,idem,der(11)t(1;11)(q23;q23)/ 46,XX,der(7)t(3;7)(?;p22),t(9;10)(p22;p1? 5),der(11)t(10;11),-13,+22

11

M/60

PV

s 46,XY,der(11)t(1;11)(q12;q14)/46,XY,del(20)(q12)

12

M/65

RAEBI

47,XY,+8,der(11)t(1;11)(q21;q14-21)

13

F/65

RAEBI

46,X,add(4)(q23),del(20)(q12),+mar/46,idem,der(11)t(1;11)(q11;q25)

 

Acute lymphocytic leukemia

14

M/4

ALL

46,XY,der(11)t(1;11)(q21;q14)

15

F/62

ALL

46,XX,der(11)t(1;11)(q21;q23)

16

M

BP-ALL

51,XY,+6,+der(11)t(1;11)(q21;q23),+19,+21,+22

17

F/8

ALL

46,XX,add(4)(q35),t(9;11)(p22;q23),der(11)t(1;11)(q21;q14)

18

M/21

BP-ALL

46,XY,der(11)t(1;11)(q21;q23)

19

F/36

s- B-ALL

46,XX,der(11)t(1;11)(q21;q23),t(12;17)(p13;q21)

20

M/16

BP-ALL

46,XY,der(6)t(1;6)(q23;p21)/46,XY,der(11)t(1;11)(q23;q21)

21

M

ALL

63,XXY,-1,-2,-3,-7,-9,+10,der(11)t(1;11)(q12;q22),-13,-15,+18,-19,-20,+21/61-66,idem,+2

22

M/50

B-ALL

45,XY,der(9)t(9;22)(q34;q11),-10,der(11)t(1;11)(q12;q25),+14,der(14;22) t(14;20)(p13;p13) t(9;22),der(15)t(1;15)(q12;p13),der(19)t(1;19)(q12;p13),der(20)t(1;20)(q12;p13),-21

 

Other hematological neoplasms

23

M/70

PCL

45,XY,der(5;20)(p10;p10),der(11)t(1;11)(q12;q23),t(11;14)(q13;q32),-13,der(20)t(5;20)(q10;p10)dup(5)

24

M/60

T-PLL

42,XY,add(1)(q21),add(7)(q22),i(8)(q10),-9,der(11)t(1;11)(q21;q23),del(12)(p12),-13,-14, -15,add(17)(p13),add(18)(q23),-22,+mar/42,idem,+8,+15,add(21)(p11)/47,XY,+21

25

M/36

ANKL

48,XY,+3,der(11)t(1;11)(q21;q25),add(22)(q13),+mar/50,idem,+13,+20

26

F

MM

55-57,XX,+X,-X,der(X;14)(q10;q10),der(1)del(1)(q21q32)inv(1)(q13q32),+3,+5,+6,+7,-8, +9,+11,der(11)t(1;11)(q12;q25),+add(12)(p11),+13,+15,+18, +18,+19,+19,+21,+22,+1-2mar

27

M/40

CLL

46,XY,del(6)(q13q21),del(7)(q22q34),-8,add(9)(q34),del(9)(q22),der(11)t(1;11)(q21;q23),-17,+r,dmin

 

Lymphomas

28

F/37

ENK/T-cell

47,X,-X,der(1)t(1;14)(p22;q11),-2,i(6)(p10),del(7)(q31q36),add(8)(p23), der(11)t(1;11)q11;q25),-18, +20,+21,-22,+3mar/49,idem,+i(6)(p10),+del(7)(q31q36) LN

29

F/78

DLBCL

43,XX,-1,?dup(3)(q21q27),der(11)t(1;11)(q23;q13),der(14)t(11;14)(q13;q32),-21LN

30

F

CLL-NHL

47,XX,+12,t(14;19)(q32;q13), 47,XX,der(11)t(1;11)(q12;q25),+12,t(12;22),t(14;19)/47,idem,add(10)(q24)LN

31

M/84

FL

48,XY,+X,der(11)t(1;11)(q12;q24),t(14;18)(q32;q21),+der(18)t(14;18)LN

32

F

DLBCL

50,XX,+X,der(2)t(2;15)(p13;q13),der(11)t(1;11)(q21;q25),+12,+del(13)(q14),der(14)t(14;15)(q32;q22), der(15)t(2;15)(p23;q13),der(16)t(7;16)(q22;q22),der(22)t(2;22)(q33;p11) LN

33

M/70

DLBCL

47,XY,del(3)(q22q25),t(4;9)(q21;q34),del(6)(q16q23),del(9)(q34),der(11)t(1;11)(q21;q13),del(12) (q22q23),+18,add(19)(q13)/46,XY,del(20)(q12)

 

Alternative 1q/11q breakpoints

34

F/70

Mature B- lymphoma

50,XX,+X,+3,+7,der(11)t(1;11)(q25;q23),-13,t(14;18)(p?;p?),-15,+3mar/50,idem,add(19) (q13)LN

35

M/46 lymph

HD

75,XX,-Y,+2,+3,+4,der(4)t(1;4)(q12;q31)x2,+i(5)(q10),-6,-6,+add(7)(p15)x2,-8,+9,-10,der(10)t(10;11) (p15;q13),i(10)(q10),+11,der(11) t(1;11)(q21q32;q13)x2,+14,-15,-17,-17,-18,+19,+20,21,i(21)(q10)x2, +hsr(?),+5mar LN

36

M/11

B-ALL

58,XY,-X,-1,-2,-3,-5,?del(6)(q23q25),-7,-9,+10,der(11)t(1;11)(q25;q11),-13,-15,-16,-17,-20, -22,+mar/ 57-59,idem,dup(1)(q12q25)/55,XX,+X,+4,+?del(6),i(7)(q10),+8,+10,der(13)t(1;13)(q25;q32),+14,+18,+19,+21

37

M

MM

52,XY,del(1)(p11p21),der(2)t(X;2)(q2?1;q25),+der(3)t(2;3)(q2?5;q28),der(4)t(4;14)(p16;q32),del(5)(q13q22),+der(5)t(5;8)(q13;q22),der(6)t(6;13)(p25;q3?3),+der(7)t(7;16)(p13;p11),der(8)t(4;8)(q28;q21),+9,del(9)(q21q33)x2,+11,del(12)(p?),-13,del(14)(q2?4),13,+15,der(16)t(1;16)(q11;q11),+der(19)t(8;19)(q23;p12)/52,XY,del(1),der(2)t(X;2),der(4)dup(4)(q2?1q3?)t(4;11)(q3?;q23),der(4)t(4;14),del(5),+der(5)t(5;8),+der(7)t(7;8)(p13;?),+9,del(9)x2,der(11)t(1;11)(q11;q2?1),der(12)(p?),del(14),+15,+19/
52, XY,del(1),der(2)t(2;4)(q24;q32),der(2)t(X;2),+der(3)t(3;7)(p11;?),der(4),del(5),+der(5),der(7)t(7;8),+9,del(9)x2,+der(11)t(1;11),del(12),del(14),+15,+19

38

F

MM

4850,XX,+del(3)(q24q28),dup(5)(q23q35),del(6)(q21),+der(6)t(6;13)(q23;q13),add(8)(p10),+9,dic(9;11)(p13;q23),der(11)t(1;11)(q10;q23),del(14)(q32),+15,+17,der(18)t(1;18)(q10;q23),+mar

39

M

MM

46-49,XY,t(3;14)(q21;q32),del(6)(q?23),der(8)t(8;19),+add(9)(p?21),der(10)t(10;12)(q24;q24),der(11) t(1;11)(q25;q23),der(12)t(12;15)(q15;q21),-13,+add(15)(p11),-16,+19, +der(20)t(1;20)(q12;q13)

40

M

FA MDS

46,XY,der(11)t(1;11)(q23;q23)/46,idem,del(6)(p21)

41

M

MM

40,X,Y,add(1)(q32),der(2)ins(2;2)(p12;q31q22)t(2;2)(p21;q32),t(2;14)(p12;q32),add(3)(p21),t(4;14)(p16;q32),add(6)(q13),der(8)t(8;21)(p11;q11),der(9)t(1;9)(p24;q31),10,der(11)t(1;11)(q23;q11),der(13) t(13;14)(q12;q11),-14,-14,add(16)(q12),-17,add(18)(p11),-20,der(20)t(1;20)(p11;q13),-21, +mar/ 80,idemx2

42

M/0

AML M4

46,XY,der(1)t(1;11)(q21;q23)t(1;11)(p12;q25)ins(1;11)(p32;q13q23),der(11)t(1;11)(q21;q23)del(11)(q13q23)

43

M/0

AML M4

46,XY,der(1)t(1;11)(q21;q23)t(1;11)(p12;q25)ins(1;11)(p32;q13q23),der(11)t(1;11)(q21;q23)del(11)(q13q23)

44

M

FL

53,X,-Y,+add(5)(q31),i(6)(p10),+7,+8,+10,der(11)t(1;11)(q23;q25),t(14;18)(q32;q21),+i(21)(q10),+3mar

45

M/58

BL

48,XY,inv(1),t(3;14;18),t(8;22)(q24;q11),add(9),der(11)t(1;11)(q25;q13),+18,+20 LN 47,XY,inv(1),t(3;14;18),t(8;22),add(9),der(11)t(1;11),add(13)(?q12),add(15)(p12),+18

46

M41

BL

46,XY,del(1)(q32),t(8;14)(q24;q32),der(11)t(1;11)(q32;q2?3),dup(13)(q2?q?)


Abbreviations: M, Male; F, Female; AML, Acute myeloid leukemia; RARS, Refractory anemia with ringed sideroblasts; CMMoL, Chronic myelomonocytic leukemia; s-, secondary; MDS, myelodysplastic syndrome; PV, polycythemia vera; RAEBI, Refractory anemia with excess blasts-1; ALL, acute lymphoblastic leukemia; BP, Bilineage or biphenotypic leukemia; CLL, Chronic lymphocytic leukemia; PCL, Plasma cell leukemia; T-PLL, T-prolymphocytic leukemia; ANKL, Aggressive natural killer-cell leukemia; MM, Multiple myeloma; ENK/T, Extranodal NK/T-cell, NHL, Non-Hodgkin's lymphoma; DLBCL, Diffuse large B-cell lymphoma; FL, Follicular lymphoma; LN, lymph node. HD., Hodgkin disease; FA., Fanconi anemia.
1. Najfeld et al., 1978; 2. González et al., 1992., 3. Muroi et al., 1996; 4. Archimbaud et al., 1998; 5-8,19. Harrison et al., 1998; 9. von Bergh et al., 2000; 10. Stark et al., 2004; 11. Douet- Guilbert et al., 2008; 12. Lange et al 2010; 13. Dambruoso et al., 2012; 14. Kaneko et al., 1982; 15. Mamaeva et al., 1983; 16. Hayhashi et al., 1990; 17. Lorenzana et al., 1991; 18. Forrest et al., 1998; 19. Harrison et al., 1998; 20. Jarvis et al., 1999; 21. Betts et al., 2001; 22. Wan et al., 2004; 23. Avet-Loiseau et al., 2001; 24. Yamaguchi et al., 2003; 25. Ryder et al., 2007; 26. Lim et al., 2013; 27. Travella et al., 2013; 28. Tien et al., 1997; 29. Jerkeman et al., 1999; 30. Qian et al., 1999; 31. Le Baccon et al., 2001; 32. Dave et al., 2002; 33. Narayan et al., 2013. 34. Reeves et al., 1980; 35. Reeves et al., 1990; 36. Martineu et al., 1996; 37. Martin et al., 1996; 38. Brigaudeauet al., 1997; 39. Sawyer et al., 1998; 40. Alter et al., 2000; 41. Smadja et al., 2003; 42-43. Watanabe et al., 2003; 44. Einerson et al., 2005; 45. Li et al., 2006; 46. Havelange et al., 2013.

Result of the chromosomal anomaly

Fusion Protein
Oncogenesis Unbalanced translocations of the long arm of chromosome 1 to the long arm of chromosome 11 are chromosomal abnormalities detectable in both hematologic neoplasms and lymphomas. Although cytogenetically heterogeneous, der(11)t(1;11)(q12-21;q14-25) results in trisomy of genes located on 1q, associated with partial monosomy of 11q. May be found as a sole abnormality or part of a simple karyotype in myeloid malignancies and ALL, suggesting that it may be important for disease initiation in these malignancies. Whereas, in the majority of cases this unbalanced rearrangement was apparently a secondary aberration -occurring in complex karyotypes or together with the well-known primary abnormalities, therefore representing clonal evolution associated with disease progression. The possible role of previous mutagenic exposure in these cases, particularly in cases with secondary diseases remains a poorly understood finding.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Fanconi anemia: myelodysplasia as a predictor of outcome
Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GV, Elghetany MT
Cancer Genet Cytogenet 2000 Mar;117(2):125-31
PMID 10704682
 
Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint
Archimbaud E, Charrin C, Magaud JP, Campos L, Thomas X, Fière D, Rimokh R
Leukemia 1998 Jan;12(1):25-33
PMID 9436917
 
Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique
Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M, Désangles F, Ramond S, Talmant P, Bataille R
Blood 2001 Feb 1;97(3):822-5
PMID 11157506
 
The investigation of karyotypic instability in the high-hyperdiploidy subgroup of acute lymphoblastic leukemia
Betts DR, Riesch M, Grotzer MA, Niggli FK
Leuk Lymphoma 2001 Jun;42(1-2):187-93
PMID 11699206
 
Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method
Brigaudeau C, Trimoreau F, Gachard N, Rouzier E, Jaccard A, Bordessoule D, Praloran V
Br J Haematol 1997 Mar;96(3):594-600
PMID 9054668
 
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome
Dambruoso I, Boni M, Rossi M, Zappasodi P, Calvello C, Zappatore R, Cavigliano PM, Giardini I, Rocca B, Caresana M, Astori C, Cazzola M, Castagnola C, Bernasconi P
Cancer Genet 2012 Jun;205(6):285-94
PMID 22749034
 
Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization
Dave BJ, Nelson M, Pickering DL, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Sanger WG
Cancer Genet Cytogenet 2002 Jan 15;132(2):125-32
PMID 11850073
 
Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions
Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M
Ann Hematol 2008 Jul;87(7):537-44
PMID 18350294
 
FISH is superior to PCR in detecting t(14;18)(q32;q21)-IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples
Einerson RR, Kurtin PJ, Dayharsh GA, Kimlinger TK, Remstein ED
Am J Clin Pathol 2005 Sep;124(3):421-9
PMID 16191511
 
Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities
Forrest DL, Nevill TJ, Horsman DE, Brockington DA, Fung HC, Toze CL, Conneally EA, Hogge DE, Sutherland HJ, Nantel SH, Shepherd JD, Barnett MJ
Br J Haematol 1998 Dec;103(3):630-8
PMID 9858210
 
Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes
González Manso AI, García Marcilla A, Barreiro E, Gilsanz F
Cancer Genet Cytogenet 1992 Jul 15;61(2):174-82
PMID 1638500
 
Ten novel 11q23 chromosomal partner sites
Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, Moorman AV, Secker-Walker LM
European 11q23 Workshop participants Leukemia
PMID 9593286
 
Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement
Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, Dastugue N, Penther D, Barin C, Collonge-Rame MA, Baranger L, Terré C, Nadal N, Lippert E, Laï JL, Cabrol C, Tigaud I, Herens C, Hagemeijer A, Raphael M, Libouton JM, Poirel HA; GFCH (Groupe Francophone de Cytogénétique Hématologique)
Genes Chromosomes Cancer 2013 Jan;52(1):81-92
PMID 23012230
 
Karyotypic patterns in acute mixed lineage leukemia
Hayashi Y, Sugita K, Nakazawa S, Abe T, Kojima S, Inaba T, Hanada R, Yamamoto K
Leukemia 1990 Feb;4(2):121-6
PMID 2137547
 
Two children with acute lymphoblastic leukemia and "jumping" translocations: both involve 1q23 as the donor breakpoint
Jarvis A, Sharma P, Watson N, Smith A
Cancer Genet Cytogenet 1999 Oct 15;114(2):112-6
PMID 10549266
 
Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas
Jerkeman M, Johansson B, Akerman M, Cavallin-Ståhl E, Kristoffersson U, Mitelman F
Eur J Haematol 1999 Mar;62(3):184-90
PMID 10089896
 
Correlation of karyotype with clinical features in acute lymphoblastic leukemia
Kaneko Y, Rowley JD, Variakojis D, Chilcote RR, Check I, Sakurai M
Cancer Res 1982 Jul;42(7):2918-29
PMID 6952960
 
Telomere shortening and chromosomal instability in myelodysplastic syndromes
Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, Göhring G
Genes Chromosomes Cancer 2010 Mar;49(3):260-9
PMID 19998444
 
Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma
Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, Esmenjaud E, Sotto JJ, Callanan M
Genes Chromosomes Cancer 2001 Nov;32(3):250-64
PMID 11579465
 
Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma
Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL
Cancer Genet Cytogenet 2006 Oct 15;170(2):140-6
 
Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore
Lim AS, Lim TH, See KH, Ng YJ, Tan YM, Choo NS, Lim SX, Yee Y, Lau LC, Tien SL, Sathish K, Tan DC
Chin Med J (Engl) 2013;126(10):1872-7
PMID 23673102
 
Immunoglobulin gene rearrangements in acute lymphoblastic leukemia with the 9;11 translocation
Lorenzana AN, Rubin CM, Le Beau MM, Nachman J, Connolly P, Subramanian U, Johnson FL, McKeithan TW
Genes Chromosomes Cancer 1991 Jan;3(1):74-7
PMID 1906342
 
Complete or partial trisomy for the long arm of chromosome 1 in patients with various hematologic malignancies
Mamaeva SE, Mamaev NN, Jartseva NM, Belyaeva LV, Scherbakova EG
Hum Genet 1983;63(2):107-12
PMID 6573295
 
Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study
Martin PL, Look AT, Schnell S, Harris MB, Pullen J, Shuster JJ, Carroll AJ, Pettenati MJ, Rao PN
J Pediatr Hematol Oncol 1996 May;18(2):113-21
PMID 8846121
 
Isochromosomes in acute lymphoblastic leukaemia: i(21q) is a significant finding
Martineau M, Clark R, Farrell DM, Hawkins JM, Moorman AV, Secker-Walker LM
Genes Chromosomes Cancer 1996 Sep;17(1):21-30
PMID 8889503
 
Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14)
Muroi K, Miyata T, Saito M, Hatake K, Amemiya Y, Miura Y
Acta Haematol 1996;96(4):251-4
PMID 8922495
 
Trisomy of 1q in preleukaemia with progression to acute leukaemia
Najfeld V, Singer JV, James MC, Fialkow PJ
Scand J Haematol 1978 Jul;21(1):24-8
PMID 279085
 
PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis
Narayan G, Xie D, Freddy AJ, Ishdorj G, Do C, Satwani P, Liyanage H, Clark L, Kisselev S, Nandula SV, Scotto L, Alobeid B, Savage D, Tycko B, O'Connor OA, Bhagat G, Murty VV
Genes Chromosomes Cancer 2013 Nov;52(11):1030-41
PMID 23929756
 
Cyclin D2 promoter disrupted by t(12;22)(p13;q11
Qian L, Gong J, Liu J, Broome JD, Koduru PR
2) during transformation of chronic lymphocytic leukaemia to non-Hodgkin's lymphoma Br J Haematol
PMID 10460609
 
Serial cytogenetic studies showing persistence of original clone in Hodgkin's disease
Reeves BR, Nash R, Lawler SD, Fisher C, Treleaven JG, Wiltshaw E
Cancer Genet Cytogenet 1990 Nov 1;50(1):1-8
PMID 2253176
 
The chromosome changes in non-Burkitt lymphomas
Reeves BR, Pickup VL
Hum Genet 1980;53(3):349-55
PMID 7372340
 
Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature
Ryder J, Wang X, Bao L, Gross SA, Hua F, Irons RD
Int J Hematol 2007 Jan;85(1):18-25
PMID 17261497
 
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping
Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B
Blood 1998 Dec 1;92(11):4269-78
PMID 9834233
 
Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases
Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, Taillemite JL, Bastard C
Genes Chromosomes Cancer 2003 Nov;38(3):234-9
PMID 14506697
 
Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel
Stark B, Jeison M, Gabay LG, Mardoukh J, Luria D, Bar-Am I, Avrahami G, Kapeliushnik Y, Sthoeger D, Herzel G, Steinberg DM, Cohen IJ, Goshen Y, Stein J, Zaizov R, Yaniv I
Br J Haematol 2004 Aug;126(3):320-37
PMID 15257704
 
Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas
Tien HF, Su IJ, Tang JL, Liu MC, Lee FY, Chen YC, Chuang SM
Br J Haematol 1997 Jun;97(3):621-5
PMID 9207410
 
Structural alterations in chronic lymphocytic leukaemia
Travella A, Ripollés L, Aventin A, Rodríguez A, Bezares RF, Caballín MR, Slavutsky I
Cytogenetic and FISH analysis Hematol Oncol
PMID 22961973
 
Pathogenesis of jumping translocations: a molecular cytogenetics study
Wan TS, Ma SK, Chow EY, Li YH, Lin SY, Chan LC
Leuk Res 2004 Oct;28(10):1075-9
PMID 15289020
 
Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings
Watanabe N, Kobayashi H, Ichiji O, Yoshida MA, Kikuta A, Komada Y, Sekine I, Ishida Y, Horiukoshi Y, Tsunematsu Y, Yano M, Nakadate H, Kaneko Y
Leukemia 2003 May;17(5):876-82
PMID 12750700
 
T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency
Yamaguchi M, Yamamoto K, Miki T, Mizutani S, Miura O
Cancer Genet Cytogenet 2003 Oct 1;146(1):22-6
PMID 14499692
 
A DNA probe combination for improved detection of MLL/11q23 breakpoints by double-color interphase-FISH in acute leukemias
von Bergh A, Emanuel B, van Zelderen-Bhola S, Smetsers T, van Soest R, Stul M, Vranckx H, Schuuring E, Hagemeijer A, Kluin P
Genes Chromosomes Cancer 2000 May;28(1):14-22
PMID 10738298
 

Citation

This paper should be referenced as such :
Zamecnikova A, Al Bahar S
der(11)t(1;11)(q11-23;q14-25);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0111q1123q1425ID1651.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(1;11)(q11-23;q14-25)

External links

Mitelman databaset(1;11)(q11-23;q14-25) [Case List]    t(1;11)(q11-23;q14-25) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9811/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9975/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9989/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseder(11)t(1;11)(q11-23;q14-25)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:54:17 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.